Inhibikase Therapeutics, Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Dec 2019 | — | $-4.5M | $18.5K |
| Mar 2020 | — | $-4.7M | $13.1K |
| Jun 2020 | — | $-4.8M | $7.8K |
| Sep 2020 | — | $-5.1M | $16.2K |
| Dec 2020 | — | $9.8M | $14.0M |
| Mar 2021 | $1.2M | $8.0M | $9.6M |
| Jun 2021 | $248.9K | $47.1M | $46.8M |
| Sep 2021 | $248.9K | $43.2M | $44.8M |
| Dec 2021 | $248.9K | $38.4M | $40.8M |
| Mar 2022 | — | $34.0M | $36.6M |
| Jun 2022 | — | $29.5M | $32.2M |
| Sep 2022 | — | $25.1M | $5.8M |
| Dec 2022 | — | $21.0M | $7.2M |
| Mar 2023 | — | $25.3M | $4.0M |
| Jun 2023 | — | $19.5M | $1.9M |
| Sep 2023 | — | $15.0M | $14.9M |
| Dec 2023 | $381.8K | $11.0M | $9.2M |
| Mar 2024 | — | $6.8M | $2.4M |
| Jun 2024 | — | $5.1M | $3.1M |
| Sep 2024 | — | $-530.6K | $913.4K |
| Dec 2024 | — | $94.9M | $97.5M |
| Mar 2025 | — | $85.7M | $73.4M |
| Jun 2025 | — | $80.1M | $77.7M |
| Sep 2025 | — | $72.9M | $38.3M |
| Dec 2025 | — | $172.9M | $178.8M |
| Mar 2026 | — | $167.6M | $49.6M |
| Jun 2026 | — | $153.3M | $31.2M |